By WSJ Staff
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Consumers will now be able to access NovoCare Pharmacy through Him & Hers' platform as well as clinical support, nutrition guidance and a membership, the companies said in a statement Tuesday.
"We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future," said Andrew Dudum, chief executive and founder of Hims & Hers.
"Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk's innovative medications with Hims & Hers ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably," said Dave Moore, executive vice president of U.S. operations and global business development and president of Novo Nordisk.
(END) Dow Jones Newswires
April 29, 2025 07:31 ET (11:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。